Research progress in immune cell therapy for hepatocellular carcinoma
HE Yulin1 MENG Zhongji1,2,3
1.Institute of Biomedical Research, Taihe Hospital of Shiyan City (Affiliated Taihe Hospital of Hubei University of Medicine), Hubei Province, Shiyan 442000, China; 2.Department of Infectious Disease, Taihe Hospital of Shiyan City (Affiliated Taihe Hospital of Hubei University of Medicine), Hubei Province, Shiyan 442000, China; 3.Hubei Key Laboratory of Embryonic Stem Cell Research, Hubei Province, Shiyan 442000, China
Abstract：Hepatocellular carcinoma is one of the most common malignant tumors in the world, especially in China with the highest morbidity. Currently, hepatocellular carcinoma is mainly treated by surgery, radiotherapy, local ablation, hepatic artery chemoembolization, molecular targeted therapy, etc. Because of the occult onset of hepatocellular carcinoma, most patients have lost the opportunity for surgery when they are discovered, and the therapeutic effect is very limited. Therefore, it is of great significance to explore new treatment options. Tumor immune cell therapy is currently the most concerned emerging treatment, especially gene modified T cell therapy has shown great potential in the treatment of hepatocellular carcinoma. This paper will review the recent advances in immunotherapy for hepatocellular carcinoma.
[1] Bray F，Ferlay J，Soerjomataram I，et al. Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin，2018，68（6）：394-424.
[2] Siegel RL，Miller KD，Jemal A. Cancer statistics，2018 [J]. CA Cancer J Clin，2018，68（1）：7-30.
[3] Xie Y，Xiang Y，Sheng J，et al. Immunotherapy for Hepatocellular Carcinoma： Current Advances and Future Expectations [J]. J Immunol Res，2018，2018：8 740 976.
[4] Calderaro J，Rousseau B，Amaddeo G，et al. Programmed death ligand 1 expression in hepatocellular carcinoma： Relationship With clinical and pathological features [J]. Hepatology，2016，64（6）：2038-2046.
[5] Wang WC，Zhang ZQ，Li PP，et al. Anti-tumor activity and mechanism of oligoclonal hepatocellular carcinoma tumor-infiltrating lymphocytes in vivo and in vitro [J]. Cancer Biol Ther，2019，20（9）：1187-1194.
[6] Kawata A，Une Y，Hosokawa M，et al. Adjuvant chemoimmunotherapy for hepatocellular carcinoma patients. Adriamycin，interleukin-2，and lymphokine-activated killer cells versus adriamycin alone [J]. Am J Clin Oncol，1995， 18（3）：257-262.
[7] Haruta I，Yamauchi K，Aruga A，et al. Analytical study of the clinical response to two distinct adoptive immunotherapies for advanced hepatocellular carcinoma：comparison between LAK cell and CTL therapy [J]. J Immunother Emphasis Tumor Immunol，1996，19（3）：218-223.
[8] Chen C，Ma YH，Zhang YT，et al. Effect of dendritic cell-based immunotherapy on hepatocellular carcinoma： A systematic review and meta-analysis [J]. Cytotherapy，2018， 20（8）：975-989.
[9] Alnaggar M，Lin M，Mesmar A，et al. Allogenic Natural Killer Cell Immunotherapy Combined with Irreversible Electroporation for Stage Ⅳ Hepatocellular Carcinoma： Survival Outcome [J]. Cell Physiol Biochem，2018，48（5）：1882-1893.
[10] Siu EH，Chan AW，Chong CC，et al. Treatment of advanced hepatocellular carcinoma： immunotherapy from checkpoint blockade to potential of cellular treatment [J]. Transl Gastroenterol Hepatol，2018，3：89.
[11] Yu SJ，Ma C，Heinrich B，et al. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma [J]. J Hepatol，2019，70（3）：449-457.
[12] Meng Y，Sun J，Wang X，et al. The biological macromolecule Nocardia rubra cell-wall skeleton as an avenue for cell-based immunotherapy [J]. J Cell Physiol，2019.
[13] Zhou Z，Qin H，Weng L，et al. Clinical efficacy of DC-CIK combined with sorafenib in the treatment of advanced hepatocellular carcinoma [J]. J BUON，2019，24（2）：615-621.
[14] Zhang Q，Zhang Z，Peng M，et al. CAR-T cell therapy in gastrointestinal tumors and hepatic carcinoma： From bench to bedside [J]. Oncoimmunology，2016，5（12）：e1 251 539.
[15] Adachi K，Kano Y，Nagai T，et al. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor [J]. Nat Biotechnol，2018，36（4）：346-351.
[16] Hu P，Cheng B，He Y，et al. Autophagy suppresses proliferation of HepG2 cells via inhibiting glypican-3/wnt/beta-catenin signaling [J]. Onco Targets Ther，2018，11：193-200.
[17] Jiang Z，Jiang X，Chen S，et al. Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma [J]. Front Immunol，2017，7：690.
[18] Liu H，Xu Y，Xiang J，et al. Targeting Alpha-Fetoprotein （AFP）-MHC Complex with CAR T-Cell Therapy for Liver Cancer [J]. Clin Cancer Res，2017，23（2）：478-488.
[19] Wang Y，Chen M，Wu Z，et al. CD133-directed CAR T cells for advanced metastasis malignancies：A phase Ⅰ trial [J]. Oncoimmunology，2018，7（7）：e1 440 169.
[20] Guo X，Jiang H，Shi B，et al. Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma [J]. Front Pharmacol，2018，9：1118.
[21] Chen L，Qiao D，Wang J，et al. Cancer immunotherapy with lymphocytes genetically engineered with T cell receptors for solid cancers [J]. Immunol Lett，2019，216：51-62.
[22] Spear TT，Callender GG，Roszkowski JJ，et al. TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumors [J]. Cancer Immunol Immunother，2016，65（3）：293-304.
[23] Zhu W，Peng Y，Wang L，et al. Identification of alpha-fetoprotein-specific T-cell receptors for hepatocellular carcinoma immunotherapy [J]. Hepatology，2018，68（2）：574-589.
2019, Vol. 16 
京公网安备 11010502046598号